PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371999
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371999
Human Embryonic Stem Cells Market Forecasts to 2030 - Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography
According to Stratistics MRC, the Global Human Embryonic Stem Cells Market is accounted for $1.8 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 11.2% during the forecast period. The inner cell mass of a human embryo during the blastocyst stage, usually 5-7 days after conception, is when human embryonic stem cells, a kind of pluripotent stem cell, are generated. The amazing capacity of these cells to develop into almost any form of cell in the human body is well recognized. They have a tremendous potential for application in regenerative medicine and research in addition to playing a critical function in early human development. It is crucial to ensure the efficacy and security of human embryonic stem-based therapeutics, to produce and deploy them, rigorous quality control procedures and safety evaluations are essential.
According to the article from DVC Stem published in August 2022, it was observed that the goal of stem cell therapy for Parkinson's disease is to replace destroyed brain cells with healthy, undifferentiated stem cells.
Market Dynamics:
Driver:
Growing technological advancements
The market for human embryonic stem cells has greatly benefited from technological improvements. With these developments, working with these cells has substantially improved in terms of effectiveness, safety, and usability, making them a more attractive alternative for research and possible therapeutic applications. Researchers can more accurately replicate the natural milieu of cells in the human body thanks to the development of three-dimensional (3D) culture models. As a result, human embryonic stem cells differentiation into certain cell types for regenerative therapy is improved. With the help of innovations like CRISPR-Cas9, the hESC genome may now be precisely edited, revolutionizing the field of gene editing. Hence all the above factors boost the market growth.
Restraint:
Concerns about the ethics of using embryonic stem cells
Studies looking into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of moral dilemmas including the killing of human embryos. Lack of appropriate government laws that specify what can be supported in the development of therapies using embryo-based stem cells may eventually limit the market's growth to some extent. Federal laws are further necessary due to the complexity of the legislation in this field so that researchers, scientists, and pharmaceutical firms can develop ESC treatment and accelerate its commercialization.
Opportunity:
Rising incidence of chronic diseases
There is a high demand for efficient therapies due to the rising prevalence of chronic diseases including diabetes, cardiovascular disease, neurological disorders, and autoimmune ailments. These diseases, which frequently include permanent tissue damage, may be treated using human embryonic stem cells -based therapy. Tissue deterioration and organ dysfunction are frequently seen in patients with chronic illnesses and are a useful resource for tackling the long-term effects of chronic illnesses because regenerative medicine techniques use them to repair, replace, or regenerate damaged tissues and organs. To determine the safety and effectiveness of human embryonic stem-based treatments for particular chronic conditions, clinical studies have been started.
Threat:
Tendency of immune rejection
Immune rejection may cause human embryonic stem cells-derived cell treatments to fail. Transplanted cells may be attacked and killed if the immune system of the recipient recognizes them as alien, making the therapy useless and it may limit the long-term advantages of therapy based on human embryonic stem cells. Even if the initial engraftment is effective, the persistent immune response may cause the transplanted cells to gradually disappear, decreasing the therapeutic effect's longevity thus hampering the market growth.
COVID-19 Impact
The pandemic interfered with laboratory research projects, particularly stem cell projects. The development of human embryonic stem cells research and clinical trials was hampered by the temporary closure or reduction of activities at several research organizations. Moreover, the progress of these trials was slowed down by site closures, challenges with patient recruiting, and safety worries and made safety and efficacy of medical research and therapy development even more important. This might result in human embryonic stem cells -based medicines receiving more thorough safety evaluations which hinder the market growth.
The totipotent stem cells segment is expected to be the largest during the forecast period
The totipotent stem cells segment is estimated to have a lucrative growth, as these are special kind of stem cell and all cell types in the human body, including extraembryonic and embryonic tissues, may be formed from these cells, which is extraordinary. They vary from pluripotent stem cells, though, in that the latter can develop into all bodily cell types except for extraembryonic tissues. Understanding how totipotent stem cells develop into distinct cell types can be aided by research employing these cells.
The stem cell biology research segment is expected to have the highest CAGR during the forecast period
The stem cell biology research segment is anticipated to witness the highest CAGR growth during the forecast period, as these are living things that can develop into many kinds of cells. Various stem cell types are also employed in medical treatments. Numerous biopharmaceutical firms have recently conducted substantial research into these compounds, which have numerous uses at the clinical stage for a variety of disorders, including cancer and neurological ailments. Due to the growing frequency of disorders like Parkinson's disease, cancer, and others, stem cell biology research will see improved growth. The market under study is thus anticipated to see a significant growth rate throughout the projected period as a result of these reasons.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to the growing government emphasis on drug discovery, healthcare investment, and advanced infrastructure for the development of technologies in drug discovery, as well as expanding development strategies used by several business verticals in the area. Furthermore, it is predicted that strict regulatory rules for medication research and related clinical studies would spur the market. The launch of biological and bio similar drugs by biopharmaceutical manufacturers in the US is another factor that is anticipated to fuel the market's expansion.
Region with highest CAGR:
Europe is projected to have the highest CAGR over the forecast period, owing to stringent laws governing the use of human embryonic stem cells for both research and therapy. The creation and endorsement of stem cell-based medicines are regulated by national regulatory organizations and the European Medicines Agency (EMA). For instance, in Europe, human embryonic stem cells -based clinical studies have been carried out or are now being done for a range of illnesses, including spinal cord injury, heart disease, and degenerative diseases. The purpose of these trials is to assess the efficacy and safety of stem cell-based treatments. To advance human embryonic stem cells research and turn it into practical applications, partnerships between academic institutions, biotech firms, and healthcare facilities are typical in this region which encourages the market.
Key players in the market:
Some of the key players profiled in the Human Embryonic Stem Cells Market include: PeproTech Inc., Astellas Pharma Inc., Merck KGaA, Lineage Cell Therapeutics Inc., PromoCell GmbH, Thermo Fisher Scientific, ViaCyte, Inc., Takara Bio Inc., STEMCELL Technologies Inc, Cell Cure Neurosciences LTD, CellGenix GmbH, ESI BIO, Lonza, Kite Pharma, Cynata, Sumanas, Inc., LifeCell, International Stem Cell Corporation, Genea BioCells and Geron
Key Developments:
In October 2023, Astellas Pharma Inc. and BioLabs Global, Incand Mitsui Fudosan, announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.
In October 2023, Merck launches new collaboration with United Nations-Guided Global Initiative on ageing to support carers; new training course provides critical skills for unpaid family carers and coincides with European Carers Day and Family Caregiver awareness month in the U.S.
In September 2023, Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
In September 2023, Thermo Fisher Scientific Inc. the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF's Alliance for Representative Clinical Trials (ARC).
Types Covered:
- Totipotent Stem Cells
- Pluripotent Stem Cells
- Multipotent Stem Cells
- Oligopotent Stem Cells
- Unipotent Stem Cells
- Other Types
Sources Covered:
- Bone Marrow
- Adult Body Tissues
- Embryonic Tissues
- Fetal tissues
- Differentiated Somatic Cells
- Other Sources
Applications Covered:
- Stem Cell Biology Research
- Regenerative Medicine
- Tissue Engineering
- Toxicology Testing
- Blood Disease Treatment
- Treatment of Cardiovascular Disease
- Other Applications
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Human Embryonic Stem Cells Market, By Type
- 5.1 Introduction
- 5.2 Totipotent Stem Cells
- 5.3 Pluripotent Stem Cells
- 5.4 Multipotent Stem Cells
- 5.5 Oligopotent Stem Cells
- 5.6 Unipotent Stem Cells
- 5.7 Other Types
6 Global Human Embryonic Stem Cells Market, By Source
- 6.1 Introduction
- 6.2 Bone Marrow
- 6.3 Adult Body Tissues
- 6.4 Embryonic Tissues
- 6.5 Fetal tissues
- 6.6 Differentiated Somatic Cells
- 6.7 Other Sources
7 Global Human Embryonic Stem Cells Market, By Application
- 7.1 Introduction
- 7.2 Stem Cell Biology Research
- 7.3 Regenerative Medicine
- 7.4 Tissue Engineering
- 7.5 Toxicology Testing
- 7.6 Blood Disease Treatment
- 7.7 Treatment of Cardiovascular Disease
- 7.8 Other Applications
8 Global Human Embryonic Stem Cells Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 PeproTech Inc.
- 10.2 Astellas Pharma Inc.
- 10.3 Merck KGaA
- 10.4 Lineage Cell Therapeutics Inc.
- 10.5 PromoCell GmbH
- 10.6 Thermo Fisher Scientific
- 10.7 ViaCyte, Inc.
- 10.8 Takara Bio Inc.
- 10.9 STEMCELL Technologies Inc
- 10.10 Cell Cure Neurosciences LTD
- 10.11 CellGenix GmbH
- 10.12 ESI BIO
- 10.13 Lonza
- 10.14 Kite Pharma
- 10.15 Cynata
- 10.16 Sumanas, Inc.
- 10.17 LifeCell
- 10.18 International Stem Cell Corporation
- 10.19 Genea BioCells
- 10.20 Geron
List of Tables
- Table 1 Global Human Embryonic Stem Cells Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 4 Global Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 5 Global Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 6 Global Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 7 Global Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 8 Global Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 9 Global Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 10 Global Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 11 Global Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 12 Global Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 13 Global Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 14 Global Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 15 Global Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 16 Global Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 17 Global Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 18 Global Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 19 Global Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 20 Global Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 21 Global Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 22 Global Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 23 Global Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 24 North America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
- Table 25 North America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 26 North America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 27 North America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 28 North America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 29 North America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 30 North America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 31 North America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 32 North America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 33 North America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 34 North America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 35 North America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 36 North America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 37 North America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 38 North America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 39 North America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 40 North America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 41 North America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 42 North America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 43 North America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 44 North America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 45 North America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 46 North America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 47 Europe Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
- Table 48 Europe Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 49 Europe Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 50 Europe Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 51 Europe Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 52 Europe Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 53 Europe Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 54 Europe Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 55 Europe Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 56 Europe Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 57 Europe Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 58 Europe Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 59 Europe Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 60 Europe Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 61 Europe Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 62 Europe Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 63 Europe Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 64 Europe Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 65 Europe Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 66 Europe Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 67 Europe Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 68 Europe Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 69 Europe Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 70 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
- Table 71 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 72 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 73 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 74 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 75 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 76 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 77 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 78 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 79 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 80 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 81 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 82 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 83 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 84 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 85 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 86 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 87 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 88 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 89 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 90 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 91 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 92 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 93 South America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
- Table 94 South America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 95 South America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 96 South America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 97 South America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 98 South America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 99 South America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 100 South America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 101 South America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 102 South America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 103 South America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 104 South America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 105 South America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 106 South America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 107 South America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 108 South America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 109 South America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 110 South America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 111 South America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 112 South America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 113 South America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 114 South America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 115 South America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 116 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
- Table 117 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
- Table 118 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
- Table 119 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
- Table 120 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
- Table 121 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
- Table 122 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
- Table 123 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
- Table 124 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
- Table 125 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
- Table 126 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
- Table 127 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
- Table 128 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
- Table 129 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
- Table 130 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
- Table 131 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
- Table 132 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
- Table 133 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
- Table 134 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
- Table 135 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
- Table 136 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
- Table 137 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
- Table 138 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
